Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 4/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307653 | 0.84 | PARP1 (0.36) | PARP1GRM2TP53POLBTNF | |
| SCHEMBL307763 | 0.81 | ALDH1A1 (0.38) | PARP1GRM2TACR1TP53POLB | |
| SCHEMBL1590467 | 0.81 | PARP1 (0.66) | PARP1GRM2HTR2CLMNAEGLN1 | |
| SCHEMBL3341729 | 0.70 | GAA (0.42) | TP53POLBLMNAKDM4E | |
| SCHEMBL307116 | 0.69 | P2RX7 (0.64) | RXFP1 | |
| SCHEMBL307484 | 0.67 | AURKA (0.33) | TP53POLBLMNA | |
| SCHEMBL1590531 | 0.66 | PARP1 (0.55) | PARP1GRM2POLBEGLN1KDM4E | |
| SCHEMBL3747700 | 0.65 | PARP1 (0.62) | PARP1GRM2HTR2C | |
| SCHEMBL8233333 | 0.64 | P2RX7 (0.46) | LMNAKDM4E | |
| SCHEMBL8229764 | 0.63 | P2RX7 (0.45) | PARP1GRM2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124562-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2124562-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | PARP1 1735/4885GRM2 321/4885TACR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.